Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in...
Year: 2024
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Olema...
Secura Bio Presented New Data from its Phase 2 PRIMO Trial of Copiktra® (Duvelisib) in Relapsed or Refractory Peripheral T-cell Lymphoma and Announced Plans for its Phase 3 TERZO Trial at the 2024 American Society of Hematology Meeting
Data from the Phase 2 PRIMO trial in 123 patients showed an overall response rate (ORR) of 48%, a complete...
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50%...
New Combination Data of Secura Bio’s COPIKTRA® (duvelisib) Presented at the 2024 American Society of Hematology Meeting
Dr. Alison Moskowitz presented results of a Phase 1 study of combination duvelisib plus ruxolitinib in relapsed/refractory (R/R) peripheral T-cell...
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
Study represents a significant step forward in Company’s mission to serve the broadest set of physician and patient needs with...
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial...
Nusano and GlyTherix Announce Lutetium-177 Supply Agreement
VALENCIA, Calif. and SYDNEY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, and...
Universe Pharmaceuticals INC Announces $15 Million Registered Direct Offering
Jiangxi, China, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (Nasdaq: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical...
Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting
NEW HOPE, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),...
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies
Data further validates the Company’s proprietary Senza5™ technology platform to engineer enabled CAR-T cell therapies PHILADELPHIA, Dec. 09, 2024 (GLOBE NEWSWIRE)...
MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units
TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER...
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on...
Nikon and eLabNext collaborate to integrate the NIS-Elements imaging platform with eLabNext’s Digital Lab Platform in the US
FRAMINGHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Nikon and eLabNext partner to enhance data integration between NIS-Elements imaging software...
DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis
New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC...
Scryb Announces Sale of its Joint Venture Interest in Fionet Rapid Response Group for CAD$3.5 million plus a Royalty
Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) ("Scryb'' or the "Company") is pleased to...
BioGene Therapeutics Appoints Patroski J. Lawson to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the...
Tinley’s Provides Corporate Update and Announces Results of Its 2024 Annual and Special Meeting of Shareholders
Toronto, Ontario and Los Angeles, California--(Newsfile Corp. - December 9, 2024) - The Tinley Beverage Company Inc. (CSE: TNY) (OTCQB:...
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in...